---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058960"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:58:48.774574+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "medium"
source: SEC EDGAR
---

# Fennec Pharma to report Q1 2024 results on May 14; conference call at 8:30am ET

## Summary
- First quarter 2024 financial results to be released before U.S. market open on Tuesday, May 14, 2024.
- Management to host conference call at 8:30 a.m. ET on May 14; registration required for dial-in.
- Webcast and replay archived on www.fennecpharma.com for 30 days.
- PEDMARK received FDA approval in September 2022; PEDMARQSI approved in EU (June 2023) and UK (Oct 2023).
- Company is commercial-stage specialty pharma focused on pediatric platinum-induced ototoxicity.

## SEC filing metadata
- accession: 0001104659-24-058960
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924058960/0001104659-24-058960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924058960/tm2413869d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058960
- JSON: https://secwatch.observer/filing/0001104659-24-058960.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.